Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTS for Before-School Dysfunction in ADHD
NCT00586157Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: ADHD Rating Scale IV at 4 weeks and ADHD Rating Scale IV (Morning) at 4 weeks. Started Sep 2006; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00586157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00586157.